News & Analysis on Biopharmaceutical Manufacturing & Bioprocessing Tech
By Natalie Morrison
- Last updated on
Formerly president and CEO of Taligen, Celniker has more than 20 years experience in building late-stage protein therapeutic discovery and development programs.
Of her new position, she said: "I am looking forward to sharing my experiences and working with the team as we move our lead program into development in 2012 and continue our efforts to translate clinical, biological and engineering insights into breakthrough products."